

**MARATHON OF HOPE CANCER CENTRES NETWORK
SCIENTIFIC PROGRESS REPORT – INDIVIDUAL COHORT**

Scientific progress reports provide information to the Terry Fox Research Institute (TFRI) about the developments and achievements of research teams against the Research Project Grant Agreement (RPGA). This information feeds into reports to Health Canada. Individual cohorts from a Consortium or Centre should use this template.

**Submission Deadline: October 31, 2024**

Please replace “Template” in the file name with the project number.

**Submit to:** **mohreporting@tfri.ca**

**Project/Cohort Number & Title:**

**Principal Investigator(s) Name(s) and Site(s):**

**Period Covered:** April 1, 2024 to September 30, 2024

**Report Submitted By:** Name, Email Address

|  |
| --- |
| **Cohort Information**  |
| Please select the relevant groups that are and/or will be included in this cohort. This information will assist TFRI with understanding the makeup of the Gold Cohort and ensure we have this information on file for all cohorts. Select all that apply. Include the number or proportion of cases the category applies to, if known – this number can be approximate, and will not be used for any official tallies. |
| Cohort type: [ ]  Prospective [ ]  Retrospective |
| Cancer type(s) profiled: Insert text here |
| Cohort includes:[ ]  Metastatic cancer cases: #/% [ ]  Patients in active clinical trial(s): #/%[ ]  Recurrent cancer cases: #/% |
| Cohort includes cases from the following underserved and underrepresented groups: Definitions for these groups can be found in the [MOHCCN Underserved and Underrepresented Populations Policy](https://www.marathonofhopecancercentres.ca/researcher-hub/policies-and-guidelines). Please only select a group if you are certain that your cohort includes cases from that group. |
| [ ]  Indigenous communities: | [ ]  all | [ ]  some: #/% |
| [ ]  2SLGBTQI+ communities: | [ ]  all | [ ]  some: #/% |
| [ ]  Children with cancer: | [ ]  all | [ ]  some: #/% |
| [ ]  Adolescents and young adults (AYAs) with cancer: | [ ]  all | [ ]  some: #/% |
| [ ]  Older adults: | [ ]  all | [ ]  some: #/% |
| [ ]  Individuals with advanced cancers: | [ ]  all | [ ]  some: #/% |
| [ ]  Individuals with rare cancers: | [ ]  all | [ ]  some: #/% |
| [ ]  Non-English or -French speaking communities: | [ ]  all | [ ]  some: #/% |
| [ ]  Newcomers to Canada: | [ ]  all | [ ]  some: #/% |
| [ ]  Rural and remote communities: | [ ]  all | [ ]  some: #/% |
| [ ]  Individuals with low socioeconomic status: | [ ]  all | [ ]  some: #/% |
| [ ]  Individuals with a disability: | [ ]  all | [ ]  some: #/% |
| [ ]  Individuals with inconsistent access to care: | [ ]  all | [ ]  some: #/% |

|  |
| --- |
| **Highlights**  |
| Using bullet points, list major achievements during the reporting period, such as new developments, presentations and publications. |
| * Insert text here.
 |

|  |
| --- |
| **Project Goals & Objectives** |
| Explain the progress made towards the deliverables set in your Research Project Grant Agreement (RPGA) for the reporting period. Provide information on altered or abandoned tasks, including the process used to reach decisions. |
| Insert text here. |

|  |
| --- |
| **Anticipated Outcomes and Impact** |
| Using plain language, briefly explain the anticipated outcomes and impact of your project, focusing on its potential to influence precision cancer medicine (directly or indirectly). If you provided this information in a previous report, please copy and paste the text here and make edits as needed. |
| Insert text here. |

|  |
| --- |
| **Success & Impact Stories** |
| Please briefly describe success and impact stories, for example collaborations, data sharing, patient outcomes, etc. TFRI may follow up with you to highlight these stories on TFRI/MOHCCN channels.**If any of the patients involved in your cohort are interested in sharing their story (e.g. their experience of receiving genomic-informed care, of participating in a research project, etc. - in writing or other format), please include a note here or contact Véronique LeBlanc (****vleblanc@tfri.ca****) directly.** |
| Insert text here. |

|  |
| --- |
| **Future Work Plan** |
| Comment on the plan in place to complete your project targets by the end of the fiscal year. |
| Insert text here. |

|  |
| --- |
| **Other Comments** |
| Insert text here. |

**Appendix 1: Certificates and Co-Funding**

Confirm the status of any project-related certificates required by Host Institutions by checking the applicable boxes below. A copy of the certificates may be required upon audit.

* Have research ethics certificates been renewed?

[ ]  Yes / [ ]  No / [ ]  Not applicable

* Have environmental, biohazard, and/or radioactive hazard certificates been renewed?

[ ]  Yes / [ ]  No / [ ]  Not applicable

* Have regulatory approvals and amendments for Human Clinical Trial been received?

[ ]  Yes / [ ]  No / [ ]  Not applicable

* Are there any changes to co-funding? If yes, please attach related documentation.

[ ]  Yes / [ ]  No / [ ]  Not applicable

**Additional Information:**

Provide additional context for any material changes to Institutional approvals.

**Appendix 2: Performance Indicators**

Please only include indicators that are **new** during this reporting period.

1. **Significant New Collaborations**

In the table below, identify the organization of the new partner/collaborator. State whether the purpose of the collaboration is to conduct research (**R**), develop technology or shared resources (**T**), or to implement best practices in cancer medicine (**I**). State whether the scope of the collaboration is targeted to a specific geographic area or group. Use the comment space to provide additional context, if required.

|  |
| --- |
| **New Arrangements to Collaborate on Precision Medicine** |
|  | **Organization****(Healthcare, Academic, For-Profit)** | **Purpose of Collaboration****(R/T/I)** | **Date Started****(dd/mm/yyyy)** | **Scope** |
| *1* | *e.g. University Health Network* | *Shared Genomic Laboratory (T)* | *01/01/2021* | *Regional*  |
| 1 |  |  |  |  |
| 2 |  |  |  |  |

Comments: Insert text here.

1. **Highly Qualified Personnel**

In the table below, summarize the number of trainees recruited. Use the comment space to provide additional context, if required.

**Trainee Type** (can be multiple): **S**cientific, **C**linical, **D**ata, **H**ealth **I**nformatics, **O**ther (specify)

**Gender:** **M**ale, **F**emale, **O**ther, **P**refer not to disclose

**Language of Training:** **F**rench or **E**nglish

|  |
| --- |
| **HQP** |
|  | **Name** | **Supervisor / Lab** | **Trainee Type(C/S/D/HI/O)** | **Start Date****(mm/yyyy)** | **Date Completed (mm/yyyy)** | **Gender****(M/F/O/P)** | **Language of Training (F/E)** |
| *1* | *e.g. Smith, Joan* | *Tremblay, Mary* | *HI* | *09/2021* |  | *F* | *F* |
| 1 |  |  |  |  |  |  |  |
| 2 |  |  |  |  |  |  |  |

Comments: Insert text here.

1. **New Knowledge Products**

In the table below, summarize new knowledge products finalized, presented or published during the reporting period. These knowledge products should address gaps, needs or trends in cancer research and precision cancer medicine. If the product uses MOHCCN data, please append an electronic copy for the MOHCCN Learning Commons. Use the comment space to provide additional context, if required.

**Type:** **L** = Presentation (including Abstract), **P** = Peer-reviewed publication, **C** = Case study, **R** = Report, **IP** = Patent application/received, **PM** = Patient material

**Audience** (can be multiple): **A**cademic, **C**linical, **H**ealthcare, **Pt** = Patients

**MOHCCN data**: **Y**es (includes MOHCCN data), **N**o

|  |
| --- |
| **New Knowledge Products in precision medicine** |
|  | **First Author** | **Short Title** | **Type****(L/P/C/R/IP/PM)** | **PubMed ID or Date (dd/mm/yyyy)** | **Audience (A/C/H/Pt)** | **MOHCCN Data (Y/N)** |
| 1 |  |  |  |  |  |  |
| 2 |  |  |  |  |  |  |

Comments: Insert text here.